Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion : Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat Degenerative Spinal Disease: A prospective, randomized, Assessor blind, multicenter trial

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

WHO International Clinical Trials Registry Platform - (2022) vom: 11. Jan. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: ;Diseases of the musculoskeletal system and connective tissue
Recruitment Status: Not yet recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-11-19, Last updated: 2022-11-24

ICTRP ID:

KCT0005610

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO004987578